Cargando…
Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
BACKGROUND: Parkinson’s disease-related psychosis increases patients’ risk of falls. Pimavanserin is an atypical antipsychotic approved in the USA in 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease-related psychosis. OBJECTIVE: We aimed to compare the risk...
Autores principales: | Layton, J. Bradley, Forns, Joan, Turner, Mary Ellen, Dempsey, Colleen, Bartsch, Jennifer L., Anthony, Mary S., Danysh, Heather E., Ritchey, Mary E., Demos, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844331/ https://www.ncbi.nlm.nih.gov/pubmed/34718963 http://dx.doi.org/10.1007/s40801-021-00284-1 |
Ejemplares similares
-
Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2022) -
Increased risk of falls and fractures in patients with psychosis and Parkinson disease
por: Forns, Joan, et al.
Publicado: (2021) -
Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States
por: Forns, Joan, et al.
Publicado: (2022) -
Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022) -
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)